Boehringer Ingelheim Release: Type 2 Diabetes: All Wales Medicines Strategy Group Recommends Jardiance (Empagliflozin) As An Option For Patients With Type 2 Diabetes In Wales
BRACKNELL, England--(BUSINESS WIRE)--Boehringer Ingelheim and Eli Lilly and Company are delighted to welcome the news that Jardiance®? (empagliflozin) has been recommended as an option for patients with type 2 diabetes in Wales.
Jardiance®? (empagliflozin) is recommended as an option for the treatment of type 2 diabetes mellitus to improve glycaemic control in adults as monotherapy when diet and exercise alone do not provide adequate glycaemic control in patients for whom use of metformin is considered inappropriate due to intolerance.1
Jardiance®? (empagliflozin) is recommended as an option for the treatment of type 2 diabetes mellitus to improve glycaemic control in adults as monotherapy when diet and exercise alone do not provide adequate glycaemic control in patients for whom use of metformin is considered inappropriate due to intolerance.1